Document is current
Any future updates will be listed below
-
Authors
Wang, Yunhe https://orcid.org/0000-0002-0923-1441
Su, Binbin
Alcalde-Herraiz, Marta
Barclay, Nicola L.
Tian, Yaohua https://orcid.org/0000-0002-9853-6991
Li, Chunxiao
Wareham, Nicholas J. https://orcid.org/0000-0003-1422-2993
Paredes, Roger
Xie, Junqing https://orcid.org/0000-0002-0040-0042
Prieto-Alhambra, Daniel https://orcid.org/0000-0002-3950-6346
- License Information
-
More Information
Article History
Received: 3 March 2024
Accepted: 9 July 2024
First Online: 29 July 2024
Competing interests
: D.P.-A. reported grants from Amgen, UCB Biopharma, Les Laboratoires Servier, Novartis, and Chiesi-Taylor, as well as speaker fees and advisory board membership with AstraZeneca and Johnson and Johnson outside the submitted work, in addition to research support from Janssen. R.P. has participated in advisory boards for Gilead, MSD, ViiV Healthcare, Theratechnologies and Lilly. His institution has received research support from Gilead, MSD, and ViiV Healthcare. The remaining authors declare no competing interests.
